$PHATPhathom Pharmaceuticals, Inc.

Active trials

• phase2A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeksrecruitingn=80
• phase1A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participantscompletedn=25
• —A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspringrecruitingn=728
• phase1A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Diseasecompletedn=24
• phase1A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Dailycompletedn=15
• phase1A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Diseasecompletedn=22
• phase1A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participantscompletedn=27
• phase3A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)completedn=776